Medsider Radio: Learn From Proven Medtech And Healthcare Experts

The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]Related Articles Are Medical Device Models the Key to Building a Lean Medtech Startup? Why Early Stage Medical Device Deals Aren’t as Bad as You May Think Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To